GSK 3532795

Drug Profile

GSK 3532795

Alternative Names: BMS 955176; GSK3532795; HIV maturation inhibitor

Latest Information Update: 03 May 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Bristol-Myers Squibb
  • Developer GlaxoSmithKline; Senopsys; ViiV Healthcare
  • Class Antivirals; Small molecules
  • Mechanism of Action HIV replication inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II HIV-1 infections

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for phase-I development in HIV-1-infections(In volunteers) in United Kingdom (PO, Suspension)
  • 25 Sep 2017 Bristol-Myers Squibb terminates a phase II trial due to GI intolerability in HIV-1 infections (Combination therapy, Treatment-experienced) in USA, Puerto Rico, Australia, Chile, Mexico, Taiwan, Argentina, Canada, Colombia, Peru, Russia, South Africa, and Thailand (PO) (NCT02386098)
  • 21 Aug 2017 Bristol-Myers Squibb terminates phase II trial in HIV-1 infections (Combination therapy, Treatment-naive) in USA, Argentina, Canada, Chile, Mexico, Puerto Rico, Poland, United Kingdom, France, Germany, Spain, Italy, South Africa and Thailand (NCT02415595)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top